Synthesis inhibition is the basis for the treatment of type 1 Gaucher disease by the glucosylceramide synthase (GCS) inhibitor eliglustat tartrate. However, the extended use of eliglustat and related compounds for the treatment of glycosphingolipid storage diseases with CNS manifestations is limited by the lack of brain penetration of this drug. Property modeling around the D-threo-1-phenyl-2-decanoylamino-3-morpholino-propanol (PDMP) pharmacophore was employed in a search for compounds of comparable activity against the GCS but lacking pglycoprotein (MDR1) recognition. Modifications of the carboxamide N-acyl group were made to lower total polar surface area and rotatable bond number. Compounds were screened for inhibition of GCS in crude enzyme and whole cell assays and for MDR1 substrate recognition.
Introduction
Two general strategies for the treatment of lysosomal storage diseases exist. The first strategy includes the replacement or restoration of the defective or absent catabolizing enzyme (e.g. the infusion of recombinant enzyme, chaperone therapy, bone marrow transplantation, or gene therapy) (1) . Enzyme replacement therapy is clinically approved for lysosomal storage diseases with peripheral manifestations but is limited by the absence of distribution of infused recombinant enzyme into the CNS and by the frequent development of auto-antibodies to the protein in patients who carry null mutations. The second strategy involves synthesis inhibition therapy (2) . Synthesis inhibition is a more recent therapeutic approach and has focused on identifying small molecule inhibitors of GCS. Two classes of these inhibitors have been described, including imino sugars and analogues of D-threo-1-phenyl-2-decanoylamino-3-morpholino-propanol (PDMP) (3) . The imino sugar N-butyldeoxynojirimycin (NBDNJ) is limited by its micromolar level inhibitory activity and limited specificity against the synthase.
The latter trait is associated with a high level of untoward effects resulting from secondary sites of action unrelated to glycolipid synthesis inhibition. These effects most notably include diarrhea, weight loss, and tremor, and limit its approved use in the United States (4). However, one distinct advantage of NBDNJ over the PDMP based homologs reported to date is its ability to distribute into the CNS.
The active lead compound that is currently in clinical trials and is structurally related to PDMP is N-((1R,2R)-1-(2,3-dihydrobenzo[b] [1, 4] dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide (Genz-112638, eliglustat tartrate) (5) . Recent phase 2 clinical trials using this drug for type 1 Gaucher disease demonstrate a level of efficacy equal to or greater than that seen for recombinant -glucocerebrosidase as evidenced by reversal of spleen and liver enlargement, correction of anemia, and improvements in thrombocytopenia and bone density (6) .
Phase 3 trials with eliglustat tartrate are currently in progress. Experimental data also support a potential role for eliglustat tartrate in the treatment of Fabry disease, another lysosomal storage disease with peripheral manifestations (7).In theory substrate inhibition might also work for six other lysosomal storage diseases with CNS involvement that include early and late onset TaySachs disease, Sandhoff disease, GM1 gangliosidosis, and types 2 and 3 Gaucher disease.
Indeed, an experimental model of genetic epistasis demonstrates markedly improved survival in a mouse model of Sandhoff disease that also lack GM2 synthase (8 (9) . We confirmed this possibility and then embarked on the design of new glycolipid synthesis inhibitors using the active pharmacophore of PDMP with a goal of retaining activity against GCS but eliminating substrate specificity for the MDR1 protein.
In this paper we report on the design and synthesis of a series of PDMP analogues that are active against GCS, the evaluation of these compounds in in vitro models of MDR1 transport, and the identification of a novel analogue that inhibits glucosylceramide (GlcCer) synthesis in both brain and peripheral organs. C. At that time, the basal chamber was sampled and uptake was stopped by washing each side of the membrane 3 times with ice-cold PBS. Vinblastine uptake into the cells, after correction for any remaining adherent extracellular contamination and transepithelial flux, was calculated as described previously (13) . To investigate the effect of experimental drugs on MDR-mediated transport, those compounds were added to the apical chamber (1-100 µM) during vinblastine uptake and the uptake and trasepithelial flux results expressed as a % of that with vehicle alone.
Methods

Materials -
In vivo studies -C57BL/6 mice were maintained on regular chow in specific-pathogen-free For control injections, phosphate buffered saline containing the same amount of HCl was used.
Inhibitors were given to 6 to 8 week old female or male C57BL/6 mice by intraperitoneal injection volume at 1% of body weight.
Mouse tissue lipid analysis -Lipid extractions of liver, kidney, and brain were performed as previously described (7). Briefly, frozen liver (~0.5 g), two kidneys (~0.3 g) and whole brain (~0.4 g) were individually homogenized in sucrose buffer (250 mM sucrose, pH 7.4, 10 mM
Hepes and 1 mM EDTA), at 0.2 g tissue/1 ml of sucrose buffer, with a Tri-R homogenizer. Each 0.8 ml of homogenate was mixed with 2 ml of methanol and 1 ml of chloroform, bath sonicated for 1 min and incubated at room temperature for 1 h. Tissue debris were removed by centrifugation at 2,400 x g for 30 min. The pellets were re-extracted by mixing with 1 ml of methanol, 0.5 ml of chloroform and 0.4 ml of 0.9% NaCl (chloroform/methanol/0.9% NaCl, 1:2:0.8), incubated at room temperature for 1 h and centrifuged at 2,400 x g for another 30 min.
Two extracts were combined and mixed with 4.5 ml of chloroform and 1.2 ml of 0.9% NaCl (chloroform/methanol/0.9% NaCl, 2:1:0.8). After centrifugation at 800 x g for 5 min, lower layer was washed with 3 ml of methanol and 2.4 ml of 0.9% NaCl. Second washing was carried with 3 ml of methanol, 2 ml of water and 0.4 ml of 0.9% NaCl followed by a 5-min centrifugation at 800 x g. The resultant lower phase was collected and dried under a stream of N 2 gas.
The analysis of neutral glycosphingolipids from mouse liver, kidney and brain was processed after alkaline methanolysis. Kidney lipids were incubated with 2 ml of chloroform and 1 ml of 0.21N NaOH in methanol for 2 h (kidney) or 7.5 h (liver and brain) at room temperature.
The lipid extract was normalized to 0.5 µmol of total phospholipid phosphate (liver and kidney) or 2 µmol of total phospholipid phosphate (brain) for high performance thin layer chromatography analysis. After alkaline methanolysis, the brain lipids were passed through a silica gel column (7). Borate-impregnated thin layer chromatography plates were developed in a two solvent system. Plates were first developed in chloroform/methanol ( GlcCer levels were quantified by comparison to known standards.
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Results
The GlcCer content of WT-and MDR1-MDCKII cells was measured as a function of inhibitor concentration to confirm that eliglustat tartrate (3a) was a substrate for the MDR1 transporter ( Fig. 2A) . A significant rightward shift in the concentration response curve was observed for the reduction in GlcCer levels in the MDR1 expressing cells. The IC 50 s for the WT and MDR1 expressing cells were 13.7 and 31.7 nM, respectively. The interaction of eliglustat with MDR1 was further examined by measuring [ number of hydrogen bond donors (HBD) and rotatable bonds (RotB). Within the constraints of the established pharmacophore for 3a (which requires maintenance of the free OH, the tertiary amine, and the absolute relative stereochemistry of the two chiral centers) we elected to focus on reducing the number of rotatable bonds and TPSA (Table 2 ). Rotatable bond number was most easily reduced in the aliphatic amide side chain by incorporation of a phenyl group (3b -3i), while TPSA was reduced by methylating the amide (3j).
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The activity of the new analogs at inhibiting GlcCer production in the disrupted cell assay is summarized in Table 2 . Benzyl carbamate analog 3b retained the enzyme inhibitory activity of 3a, confirming a similar observation by Jimbo et al. (15) in a related template. The corresponding 3-propionamide 3c, lower in TPSA than 3b, was equally potent. Adjusting the length of the tether to the phenyl group revealed that a 3-carbon tether (3e) was optimal (IC 50 = 80 nM). Conformational restriction of the tether to further reduce number of rotatable bonds was explored with analogs 3f -3i. Among these, 2-indanylmethyl analog 3h displayed a striking improvement in activity (IC 50 = 27 nM) and, to our knowledge, represents the most potent GCS inhibitor reported to date.
The activity of the compounds at inhibiting GlcCer production in whole WT-MDCKII cells is also summarized in Table 2 . Eliglustat (3a) was almost 10-fold more potent in intact cells The MDR-MDCKII cell line was used to help predict BBB permeability because it expresses an efflux transporter that is physiologically relevant to the brain endothelium (18, 19).
We assumed that IC 50 s for inhibition of GlcCer production in these cells would correlate directly with intracellular drug levels, thereby providing a convenient and sensitive estimate of susceptibility to MDR-mediated efflux when compared with IC 50 s in WT-MDCKII cells. Results are included in Table 2 The full range of active carboxamide inhibitors was compared using both the GCS inhibition and vinblastine transport assays in WT-versus MDR1-MDCKII cells. There was reasonable agreement between the two assays with regard to changes in the presence of MDR1
( Fig. 3D; r=0 .50). Based on these results and the IC 50 against the cell lysate synthase activity, 3h
(CCG-203586) was chosen as a lead compound for in vivo studies. Six-week old wild type mice were initially treated with 10 mg/kg/day of 3h, or vehicle for 3 days and sacrificed 12 hours after the last injection (Fig. 4) . A ten percent decrease in the GlcCer levels in the brains of 3h inhibitor treated mice was observed without changes in the eliglustat or vehicle treated mice. When a higher dose of inhibitor was employed (30 mg/kg q 12 h for 3 days), a more significant fall in brain GlcCer levels was observed (17%) in 3h inhibitor treated mice without any changes in the vehicle treated or eliglustat treated mice. By contrast eliglustat lowered liver and kidney GlcCer levels, consistent with its previously reported effects. These data confirmed the ability of 3h to cross the BBB and inhibit GCS. The mice tolerated treatment with both doses of 3h well displaying no weight loss or obvious gastrointestinal, respiratory, or behavioral changes.
Discussion
Property modeling of compounds retaining the well-established PDMP pharmacophore and four screening assays were employed in an attempt to find GCS inhibitors that would be active in the brain. Specific findings included the following. First, a series of PDMP analogues were designed to lower or eliminate their recognition as substrates for the MDR1 transporter by comparison of selected physical properties to drugs known to cross the BBB. Several compounds retained nanomolar activity as GCS inhibitors in both crude cell enzyme and whole cell assays.
The activity of these compounds confirmed the utility of the pharmacophore of PDMP as a scaffold for GCS inhibitors. Second, one analog (3h), was demonstrated to be a particularly poor substrate for the MDR1 protein relative to the other analogs using two in vitro assays based on the stable expression of MDR1. Third, the 3h analog demonstrated significant in vivo activity in lowering brain GlcCer levels after 3 days of intraperitoneal administration. The decrease in brain
GlcCer was in contrast to eliglustat tartrate, which had no discernable effect on brain GlcCer when administered in parallel.
A wealth of scholarship exists about the differences in the physical chemical properties of Overall these results suggest that recognition by MDR1 within this series is much more dependent on conformation than on small changes in lipophilicity or TPSA. Indeed, when energy-minimized conformations of compounds 3c, 3e, 3h, 3i and 3j were overlaid, significant differences were apparent ( However, for two pairs of compounds (3i/3j vs 3e/3f) which showed similar effects on The final assay employed was measurement of GlcCer levels in vivo. While MDR is important for the efflux of many therapeutics at the BBB, there are also other active efflux mechanisms that impact brain penetration (e.g. breast cancer related protein (9)). The role of such transporters can be examined using overexpressing cell lines (as used here for MDR).
However, because of the complexity of the efflux systems present at the BBB, it was more efficient to employ an in vivo assay to determine whether our lead compound could penetrate the brain at sufficient concentrations to impact GCS. Importantly, with short term dosing, inhibitor 3h was observed to significantly lower brain GlcCer levels. This effect was specific for this analogue in that eliglustat failed to demonstrate any change in brain cerebroside content under identical dosing conditions, even though it significantly lowered liver and kidney glycolipids.
This finding confirmed that developing a high affinity GCS inhibitor (3h) with a lack of recognition by MDR1 is able to result in a pharmacological response in the brain.
In summary, the present study outlines a general strategy for the design and testing of compounds that lack MDR1 affinity and identifies a new PDMP analogue that appears to satisfy the properties of high inhibitory activity against GCS and limited MDR1 affinity. (14) . 
